Nuvation Bio Inc. Total Liabilities
Nuvation Bio Inc. (NUVB) had Total Liabilities of $490.64 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $490.64M.
- 2026-03-31: Liabilities $290.68M.
- 2025-12-31: Liabilities $289.11M.
- 2025-09-30: Liabilities $275.68M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $490.64M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $290.68M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $289.11M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $275.68M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | $274.32M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $73.03M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $76.84M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $68.86M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $62.66M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $19.08M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $16.36M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $19.28M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $16.78M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $15.99M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $17.07M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $18.55M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $26.66M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $28.24M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $30.15M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $28.43M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $25.33M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $25.71M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $6.71M 10-K · filed 2022-02-28 | $2.80M 10-K · filed 2021-03-11 |
| 2020-09-30 | $974.03K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |